Insights Into Breast Cancer 2020 Midwest
Perspectives from community physicians from the midwest region of the US on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents
Midwest – September 16, 2020
Faculty Chair
William Gradishar, MD, FACP
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
REPORT SNAPSHOT
Treatment of HR-Positive Advanced Breast Cancer
- Initial endocrine therapy: Single agent vs combination with CDK4/6 inhibitor
- Targeted therapy for PIK3CA-mutated disease
- Treatment of progressive disease: Choice of next-line endocrine therapy, impact of prior treatment, monotherapy vs combinations with targeted agents (eg, everolimus, CDK4/6 inhibitor [beyond progression?])
- When to switch to chemotherapy, choice of initial and later-line treatment
Treatment of HER2-Positive Advanced Breast Cancer
- Initial therapy: Is dual HER2 blockade the standard?
- Treatment of progressive disease: TDM-1 vs other options
- Next-generation anti-HER2 agents
Treatment of Triple-Negative Advanced Breast Cancer
- Initial chemotherapy – preferred regimen, role of platinum compounds in practice, taxane selection (eg, nab-paclitaxel)
- Later lines of chemotherapy – role of eribulin and other agents, impact of prior therapy
- Role of PARP inhibitors – approach to germline and somatic BRCA mutation testing, current views on “BRCAness” and homologous recombination deficiency as biomarkers
- Immunotherapy (± nab-paclitaxel)
- Promising investigational targets and immunotherapy
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- The group of advisors comprised community oncologists from the midwest region of the US.
